What Travere Therapeutics (TVTX)'s Pre-PDUFA Insider Stock Sales Mean For Shareholders

• In late December 2025, Travere Therapeutics disclosed insider share sales by two executives executed under pre-arranged 10b5-1 trading plans, just weeks before the scheduled January 13, 2026 FDA Prescription Drug User Fee Act decision on FILSPARI’s potential label expansion in focal segmental glomerulosclerosis (FSGS).
• This timing has drawn attention because the upcoming FDA ruling on what could become the first approved FSGS treatment may materially influence Travere’s future revenue profile and regulatory risk balance.
• We’ll now examine how insider selling so close to the FILSPARI FSGS PDUFA date could influence Travere Therapeutics’ investment narrative.

Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.

Travere Therapeutics Investment Narrative Recap

To own Travere Therapeutics today, you need to believe FILSPARI can become a meaningful kidney disease franchise across IgA nephropathy and potentially FSGS, while the company manages its current unprofitability and spending. The recent insider sales, executed under 10b5-1 plans, do not appear to change the core near term catalyst, which remains the January 13, 2026 FDA decision on FILSPARI’s FSGS label expansion and the related regulatory risk.

The September 10, 2025 update on FILSPARI’s supplemental NDA in FSGS is especially relevant here, as the FDA set the January 13, 2026 PDUFA date and confirmed no advisory committee meeting. That announcement tied the DUPLEX proteinuria data directly to kidney failure risk reduction, framing how central this PDUFA outcome is for Travere’s revenue mix, its dependence on FILSPARI, and the balance between R&D investment and future cash generation.

Yet with Travere still heavily reliant on FILSPARI and facing evolving regulatory requirements, investors should be aware of the risk that...

Read the full narrative on Travere Therapeutics (it's free!)

Travere Therapeutics' narrative projects $832.7 million revenue and $221.2 million earnings by 2028.

Uncover how Travere Therapeutics' forecasts yield a $41.64 fair value, a 5% upside to its current price.

Exploring Other Perspectives

Ten fair value estimates from the Simply Wall St Community span roughly US$19 to US$119 per share, showing how far apart individual views can be. As you weigh these against the upcoming FILSPARI FSGS PDUFA decision, you can see how different assumptions about regulatory outcomes and revenue concentration can shape very different expectations for Travere’s performance.

Explore 10 other fair value estimates on Travere Therapeutics - why the stock might be worth less than half the current price!

Build Your Own Travere Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Travere Therapeutics research is our analysis highlighting 2 key rewards that could impact your investment decision.
• Our free Travere Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Travere Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Rare earth metals are the new gold rush. Find out which 38 stocks are leading the charge.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com